@article{26109, author = {Moura RS and Penna GO and Paula Vaz Cardoso L and Pontes MAA and Cruz R and S{\'a} Gon{\c c}alves H and Penna MLF and Stefani MMA and B{\"u}hrer-S{\'e}kula S}, title = {Description of Leprosy Classification at Baseline Among Patients Enrolled at the Uniform Multidrug Therapy Clinical Trial for Leprosy Patients in Brazil.}, abstract = {

The uniform multidrug therapy clinical trial, Brazil (U-MDT/CT-BR), database was used to describe and report the performance of available tools to classify 830 leprosy patients as paucibacillary (PB) and multibacillary (MB) at baseline. In a modified Ridley and Jopling (R\&J) classification, considering clinical features, histopathological results of skin biopsies and the slit-skin smear bacterial load results were used as the gold standard method for classification. Anti-phenolic glycolipid-I (PGL-I) serology by ML Flow test, the slit skin smear bacterial load, and the number of skin lesions were evaluated. Considering the R\&J classification system as gold standard, ML flow tests correctly allocated 70\% patients in the PB group and 87\% in the MB group. The classification based on counting the number of skin lesions correctly allocated 46\% PB patients and 99\% MB leprosy cases. Slit skin smears properly classified 91\% and 97\% of PB and MB patients, respectively. Based on U-MDT/CT-BR results, classification of leprosy patients for treatment purposes is unnecessary because it does not impact clinical and laboratories outcomes. In this context, the identification of new biomarkers to detect patients at a higher risk to develop leprosy reactions or relapse remains an important research challenge.

}, year = {2015}, journal = {The American journal of tropical medicine and hygiene}, issn = {1476-1645}, url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458838/pdf/tropmed-92-1280.pdf}, doi = {10.4269/ajtmh.14-0049}, language = {eng}, }